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Mesenchymal stem cells (MSCs) are known to limit immune responses in vivo by multiple 
soluble factors. Dickkopf-3 (DKK3), a secreted glycoprotein, has recently been identified 
as a novel immune modulator. Since DKK3 has been reported to be produced by MSCs, 
we investigated whether DKK3 contributes to the immune suppression of anti-tumor 
responses by MSCs. Whereas wild-type MSCs inhibited immune responses against 
two different transplantation tumors, DKK3-deficient MSCs did not affect the rejection 
process. Increased CD8+ T cell and reduced M2-type macrophages infiltration was 
observed in tumors inoculated together with DKK3-deficient MSCs. Thus, DKK3 could 
alter the composition of the tumor stroma, thereby supporting the MSCs-mediated 
suppression of immune responses against these tumor transplants.
Keywords: Dickkopf-3, mesenchymal stem cell, anti-tumor response, T cell, tumor stroma, melanoma
inTrODUcTiOn
Besides their well-known regenerative capacity, mesenchymal stem cells (MSCs) are involved 
in limiting undesirable immune responses, such as hypersensitivity, autoimmune disease, or 
alloreactivity against transplants (1–3). It has been reported that MSCs can suppress human graft-
versus-host disease (4) and murine experimental autoimmune encephalomyelitis (5). Also in the 
contact-dependent hypersensitivity disease, systemically infused MSCs can sufficiently ameliorate 
local immune responses (6). Multiple clinical trials have been launched to test the capacity of MSCs 
to limit immunological diseases in humans (3). However, besides the potentially promising clinical 
applications, the immune-regulatory capacities of MSCs also support tumor growth by inhibiting 
T cells proliferation (7, 8), by inducing regulatory T cells (9), and by facilitating the generation of 
immunosuppressive M2-type macrophages (10). Multiple soluble factors, such as TGFβ (9), prosta-
glandin E2 (11, 12), and kynurenine (13, 14) were found to be involved in the immune-suppressive 
function of MSCs.
Dickkopf-3 (DKK3) is a member of an evolutionary conserved gene family encoding for five 
secreted glycoproteins (15, 16). It is mainly produced by tissue cells in so-called immune privileged 
sites, such as brain, eye, and testis (17). In addition, DKK3 expression was found in human MSCs 
(18, 19). We recently identified DKK3 as a novel immune-mediator limiting CD8+ and CD4+ T 
cell-mediated responses (20–22). In a transgenic mouse model of peripheral T cell tolerance, we 
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showed that CD8+ T cells, which were neonatally tolerized 
toward a self-antigen exclusively expressed on keratinocytes, 
expressed DKK3. The function of these regulatory CD8+ T cells 
was dependent on the presence of DKK3 (20). Moreover, genetic 
deletion or antibody-mediated neutralization of DKK3 led to an 
exacerbated experimental autoimmune encephalomyelitis. This 
phenotype was accompanied by an increased T cell accumulation 
and a change in their polarization, displayed by an increase of 
interferon-gamma (IFNγ)-producing CD8+ and CD4+ T cells 
exclusively within the central nervous system (CNS) (21). We 
also found that DKK3 contributed to the immuno-suppressive 
microenvironment protecting transplanted, class-I mismatched 
embryoid bodies from T-cell-mediated rejection (21). DKK3 is 
also involved in regulating the composition of the B cell com-
partment (23). The development of B2 cells was impaired at the 
pre- and immature B cell stage in the absence of DKK3, resulting 
in decreased numbers of follicular B cells in adult DKK3-deficient 
mice. Furthermore, DKK3 limited B1 cell self-maintenance in the 
periphery, by decreasing the survival and proliferation of B1 cells. 
In addition, DKK3-deficient mice exhibited altered antibody 
responses and an increased secretion of the cytokine IL-10 (23).
Based on these findings, we investigated whether DKK3 is 
involved in MSCs-mediated immune modulation of anti-tumor 
responses. Our studies show that DKK3 produced by MSCs is 
required to maintain a tumor-promoting environment by limit-
ing CD8+ T cell but supporting M2-type macrophage infiltration. 
Loss of DKK3 in tumor-associated MSCs results in delayed tumor 
growth or rejection. Thus DKK3 is an additional factor involved 
in the immune-suppressive function of MSCs.
MaTerials anD MeThODs
Mice
Male C57BL/6 (B6) or RAGE-EGFP+/+xB6 (EGFP+) mice were 
used in different experiments. DKK3 knock-out (DKK3−/−) mice 
were mice with systemic deletion of DKK3 expression (17). 
Mice were bred and housed under specific pathogen-free (SPF) 
conditions in the central animal laboratory in German Cancer 
research Center (DKFZ). Animal welfare and experiments were 
achieved in accordance with institutional guidelines provided 
by the German Cancer Research Center and were approved by 
the Regierungspräsidium Karlsruhe (DKFZ205 and G177/12), 
Germany.
cell culture
Selected MSCs and HCmel12 melanoma cells were cultured in 
complete high-glucose (4.5 mg/ml) DMEM with 10% FBS, 25 mM 
HEPES, and 2 mM l-glutamine. Accutase (#A6964, Sigma) was 
used to detach the cells. RMA-mOVA T lymphoma cells were 
cultured in complete RPMI1640 with the same supplements.
Mesenchymal stem cells isolation
Isolation of MSCs was based on the protocol described before 
(24, 25) and the manufacturer’s guides from STEMCELL 
Technologies by which the MesenCult™ selection medium 
system (#05501 and #05502, STEMCELL Technology) was pro-
duced. The femur and tibia bones were isolated from two mice 
scarified by CO2. Furs and muscles were removed by scalpels. 
Openings were trimmed at two ends of the bones to allow the 
bone marrows to be washed out by isolation buffer (1× PBS 
with 2%FBS and 1 mM EDTA). Washed out bone marrow was 
suspended in isolating buffer and kept on ice. Bones were then 
cracked down by scalpels into small fragments without scratching 
and damaging the bone membranes. Fragments of bones were 
soaked in digesting medium (1× PBS with 20% FBS and 0.25% 
collagenase type-I) in room temperature for 5 min. Soaked bone 
fragments were further cracked into fine pieces. The digesting 
buffer was then filled up to 10 ml and the containing tubes were 
gently vortexed in 37°C for 45  min. Treated bone pieces were 
suspended by directly adding isolation buffer to final volume of 
30  ml and then filtered through 70 μm cell strainers. The cell 
strainers were washed by additional 10 ml isolation buffer. Cells 
from bone and bone marrow were centrifuged and the respective 
cell pellets were suspended in MesenCult™ selection medium. 
Cells were cultured in the selection medium for at least 3 weeks. 
After checking for expression of MSCs surface markers, the 
selection medium was gradually replaced by complete DMEM. 
When the differentiating capacities of these cells were confirmed, 
the MSCs were cultured only in complete DMEM for further 
experiments.
Mesenchymal stem cells Differentiation
The differentiating medium for adipogenesis was prepared by 
MesenCult™ selection medium containing 5  μg/ml insulin 
(#I6634, Sigma), 50 μM indomethacin (#I7378, Sigma), 1 μM 
dexamethasone (#D4902, Sigma), and 0.5 μM IBMX (#I7018, 
Sigma). The medium for osteogenesis was MesenCult™ selec-
tion medium containing 20 mM β-glycerol phosphate (#G9891, 
Sigma), 1  nM dexamethasone (#D4902, Sigma), and 0.5  μM 
ascorbate 2-phosphate (#A8960, Sigma). 2 ×  105 MSCs were 
seeded in six-well microplates 1  day before the inducing of 
differentiation. On the day of inducing differentiation, culture 
medium was replaced by differentiating medium. The differen-
tiating medium was changed every 3  days for 3  weeks. Three 
weeks later, the medium was removed and the cells were washed 
with 1× PBS twice and then fixed with 10% formalin in room 
temperature for 20  min. After the fixation, cells were washed 
with 1× PBS and then processed for staining. For staining of 
adipocytes, 0.5% Oil Red O (#O0625, Sigma) was dissolved 
in methanol. For staining of osteogenesis, 2% Alizarin Red S 
(#S5533, Sigma) was dissolved in distilled water in pH 4.1. Fixed 
cells were stained by indicated solution in room temperature 
for 20 min and then washed twice with 1× PBS before filled up 
with 2 ml 1× PBS and observed by optical microscope in 40× 
magnificence.
Tumor growth and isolation
4 × 105 cells of HCmel12 or RMA-mOVA cells mixed with equal 
numbers of WT or DKK3−/− MSCs were washed three times with 
1× PBS and then suspended in 200 μl 1× PBS. Mice were shaved 
and subcutaneous injection was performed to inoculate the cells 
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at the right flank of mice. Tumor size was measured in mm and 
calculated by the following equation: 0.5 ×  (width)2 ×  (length) 
for approximate volume (26). For analysis of tumor-infiltrating 
cells and surface markers of MSCs, tumors were isolated 14 days 
after inoculation. Mice were sacrificed by CO2 and tumor nodules 
were taken out by scissors and forceps. Isolated tumor nodules 
were cut into smaller pieces and then digested by digesting buffer 
containing collagenase IV and DNase I in room temperature for 
3 h. Digested tissues were filtered through 40 μm cell strainer and 
washed by complete RPMI 1640 medium. Collected cells were 
then ready for FACS staining.
Flow cytometry
To stain surface markers, harvested cells were washed twice 
with staining buffer (3% FBS and 0.1% sodium azide in DPBS) 
and stained with antibody combinations diluted in staining 
buffer in the dark on ice for 30  min. Stained cells were then 
washed twice before analysis on the BD FACSCanto™ II flow 
cytometry. For intracellular staining of DKK3, the fixation and 
permeabilization was carried out with the buffer sets (#560409, 
BD and 88-8824-00, eBioscience) according to manufacturer’s 
instructions.
Western Blotting
Mesenchymal stem cells or RMA-mOVA cells were lysed directly 
on the 10 cm petri dishes or in pellet by M-PER™ mammalian 
protein extraction reagent (#78501, Thermo Fischer Scientific) 
containing cocktails of protease (#04693159001, Roche Life 
Science) and phosphatase inhibitors (#5872, Cell Signaling 
Technology) after being washed by 1× PBS for two times. Cell 
debris was removed by 13000  rpm. Centrifugation was done 
for 10 min. Supernatants containing proteins of interest were 
analyzed by Western blotting by using mini-gel system from 
BioRad for the SDS-PAGE. Acrylamide gels were prepared in 
10% of acrylamide concentration. Proteins were transferred 
by Trans-Blot® SD Semi-Dry Transfer Cell and detected by 
specific primary antibodies and HRP-conjugated antibodies. 
The results were visualized by HRP substrates (#WBKLS0100, 
Merck Millipore) and optical films according to the manufac-
turer’s guides.
antibodies
For analysis by flow cytometry: anti-mouse CD3ϵ PerCP-
eFluor®710 (clone 17A2, #46-0032-82 eBioscience); anti-mouse 
CD4 Pacific Blue™ (clone RM4-5, #100531 BioLegend); anti-
mouse CD8α APC-Cy7 (clone 53-6.7, #100714 Biolegend); 
anti-mouse CD11b PE-Cy7 (clone M1/70, #101216 Biolegend); 
anti-mouse CD29 biotinylated (clone HMβ1-1, #102203 
Biolegend); anti-mouse/human CD44 PE-Cy7 (clone IM7, 
#103030 Biolegend); anti-mouse CD105 biotinylated (clone 
MJ7/18, #120404 Biolegend); anti-mouse CD206(MMR) 
Brilliant Violet 421™ (clone C068C2, #141717, Biolegend); anti-
mouse F4/80 AlexaFluor® 647 (clone BM8, #123122 Biolegend); 
anti-rabbit IgG HRP-linked Antibody (#7074 Cell Signaling 
Technology); Cofilin (D3F9) XP® Rabbit mAb (#5175 Cell 
Signaling Technology); anti-DKK3 antibody (20).
statistics
ANOVA followed by the Holm-Šídák approach to multiple 
comparisons was applied throughout the studies except for the 
analysis on phenotypes of MSCs, for which the unpaired t-test 
was applied.
resUlTs
DKK3 expression by Mscs is essential 
for Their suppressive activity of  
anti-Tumor responses
First, we confirmed that DKK3 expression can be detected in 
wild-type (WT) MSCs and is absent in MSCs derived from bone 
marrow of DKK3-deficient mice (DKK3−/− MSCs) (Figure 1A). 
To test the immunosuppressive activity of MSCs, the HCmel12 
melanoma transplantation tumor model was employed. Growth 
of these tumor cells in C57BL/6 mice was significantly acceler-
ated when tumor cells were injected together with WT MSCs 
in comparison to tumors inoculated without any MSCs or with 
DKK3−/− MSCs (both p < 0.0001) (Figure 1B). No difference was 
observed between the growth of tumor with DKK3−/− MSCs and 
without any MSC (p = 0.1175) (Figure 1B). This suggested that 
DKK3 might be essential for MSCs to promote tumor growth.
To exclude the possibility that the observed decrease in tumor 
growth in the presence of DKK3−/− MSCs was due to poorer 
survival or loss of MSC characteristics in vivo, we compared the 
viability and MSC phenotypes of WT and DKK3−/− MSCs. MSCs 
were derived from bone marrow of EGFP+ C57BL/6 or EGFP+ 
DKK3−/− mice and inoculated into C57BL/6 mice together with 
HCmel12 melanoma cells (Figures  1C,D). On day 14, single 
cell suspensions of the isolated tumors were generated and the 
respective EGFP+ cells identified. The percentage of DKK3-
sufficient and -deficient MSCs within the respective tumors was 
comparable (Figure 1C). Antibody staining for the MSC marker 
proteins CD29, CD44, and CD105 and flow cytometry was used 
to determine the phenotype of the isolated MSCs (Figure 1D). 
Expression of CD29 was similar for both types of MSCs isolated 
from the tumors while the CD105+ cells were even increased in 
DKK3−/− MSCs (p = 0.0014). Moreover, DKK3−/− MSCs are as 
capable as WT MSCs for undergoing in  vitro adipogenesis or 
osteogenesis (Figure 1E). Thus, DKK3−/− MSCs were normally 
persistent and maintained their phenotypes within the tumor 
transplants.
DKK3 expression by Mscs contributes 
to Modulating the composition of  
Tumor-infiltrating immune cells
Next, we analyzed tumor-infiltrating immune cells of HCmel12 
tumors 14 days after inoculation into EGFP+ C57BL/6 mice. 
The percentage of CD8+ T cells among CD3+ EGFP+ cells was 
decreased in tumors containing WT MSCs in comparison 
with tumors inoculated without any MSCs (p =  0.0142). In 
contrast, tumor-infiltrating CD8+ T cells were significantly 
increased in tumors containing DKK3−/− MSCs in comparison 
to tumors inoculated with WT MSCs or tumors without any 
FigUre 1 | DKK3 expression by Mscs is essential for their suppressive activity of anti-tumor responses. (a) DKK3 expression was detected in wild-type 
mesenchymal stem cells by flow cytometry. (B) 4 × 105 HCmel12 cells with or without equal number of mesenchymal stem cells (MSCs) were inoculated 
subcutaneously into B6 mice. Better growth in size and speed was observed when tumor cells were inoculated together with DKK3-competent MSCs (⚬, n = 13) in 
comparison with DKK3−/− MSCs (⚫, n = 13) or without any MSCs (◾, n = 13) (p < 0.0001 or p < 0.0001). No difference was observed between the growth of tumor 
with DKK3−/− MSCs and without any MSC (p = 0.1175). Two independent experiments were performed. ANOVA followed by the Holm-Šídák approach to multiple 
comparisons was applied. (c) 4 × 105 EGFP-positive wild-type MSCs (n = 7) or DKK3−/− MSCs (n = 7) were subcutaneously inoculated together with equal number 
of HCmel12 cells into B6 mice. Fourteen days later, there was no difference in the percentage of wild-type and DKK3−/− EGFP+ cells recovered from the HCmel12 
tumor nodules (p = 0.1309). (D) When identifying tumor-associated MSCs with mesenchymal stem cell marker in HCmel12 tumor, no change was observed on 
CD29+CD44+ population (p = 0.1053). However, CD44+CD105+ cells were significantly increased in DKK3−/− MSCs (p = 0.0014). Two independent experiments 
were performed. Unpaired t-test was applied between two groups. (e) In vitro differentiation showed that DKK3−/− MSCs maintained competent differentiation 
capacity as their wild-type counter part in adipogenesis and osteogenesis. The solid arrows indicate adipocytes or calcified areas.
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FigUre 2 | DKK3 expression by Mscs contributes to modulating the composition of tumor-infiltrating immune cells. (a) 4 × 105 HCmel12 melanoma 
tumor cells only (◾, n = 6) or with equal number of MSCs (⚬, wild-type, n = 6; ⚫, DKK3−/−, n = 5) were inoculated subcutaneously into EGFP+ mice with B6 
background. Fourteen days later, tumor nodules were isolated and the infiltrating EGFP+ cells were analyzed by flow cytometry. A significant reduction in the 
percentage of infiltrating CD8+ T cells was detected in tumors with wild-type MSCs in comparison with tumors without any MSC (p = 0.0142). In contrast, an 
increased infiltration of CD8+ T cells was observed for tumors with DKK3−/− MSCs in comparison with tumors with wild-type MSCs (p < 0.0001) or with tumors 
without any MSC (p = 0.0076). (B) A higher percentage of CD11b+ cells was found in wild-type MSCs-associated tumors in comparison with the tumor only group 
(p = 0.0136), whereas tumor-infiltrating CD11b+ cells were significantly decreased in tumors containing DKK3−/− MSCs in comparison with tumors containing 
wild-type MSCs (p < 0.0001) and in comparison with HCmel12 tumors without any MSC (p = 0.0141). (c) M2-type macrophages were defined as F4/80hiCD206hi 
cells out of CD11b+ cell population. A higher percentage of M2-type macrophages was found in tumors with wild-type MSCs in comparison to tumors containing 
DKK3−/− MSCS (p = 0.0033) and with tumors without any MSC (p < 0.0001). The level of M2-type macrophages remained higher in tumors containing DKK3−/− 
MSCs in comparison with tumors without any MSC (p = 0.0025). Two independent experiments were performed. ANOVA followed by the Holm-Šídák approach to 
multiple comparisons was applied for the analysis.
December 2015 | Volume 6 | Article 6455
Lu et al. Dickkopf-3-Producing MSCs Promote Tumor Growth
Frontiers in Immunology | www.frontiersin.org
MSCs (p < 0.0001 and 0.0076) (Figure 2A). Furthermore, a 
higher percentage of CD11b+ cells among EGFP+ cells was 
found in tumors with WT MSCs in comparison with tumors 
with DKK3−/− MSCs or without any MSCs (p  <  0.0001 
and p  =  0.0136) (Figure  2B). F4/80hiCD206hi M2-type 
macrophages were significantly expanded among CD11b+ 
cells in tumors with WT MSCs in comparison with tumors 
with DKK3−/− MSCs or without any MSCs (p =  0.0033 and 
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p <  0.0001) (Figure  2C). Thus, DKK3 expression by MSCs 
contributed to modulating the tumor microenvironment by 
limiting CD8+ T cell infiltration and promoting M2-type 
macrophage appearance.
DKK3 expression exclusively by Mscs is 
sufficient to limit T cell responses 
against the strongly antigenic  
rMa-mOVa Tumor
To investigate whether DKK3 produced by MSCs could also limit 
the growth of a strongly antigenic tumor, we used the RMA-
mOVA tumor cell line. These tumor cells express membrane-
bound Ovalbumin (OVA) and elicit a strong cytotoxic T cell 
response in C57BL/6 mice (27). Furthermore, these tumor cells 
do not express DKK3 (Figure 3A). RMA-mOVA tumors inocu-
lated together with WT MSCs were accepted by C57BL/6 mice, 
whereas RMA-mOVA tumors without MSCs or with DKK3−/− 
MSCs were rejected (Figure 3B). Furthermore, we observed that 
RMA-mOVA tumor-infiltrating CD8+ T cells were significantly 
increased in tumors containing DKK3−/− MSCs in comparison 
to tumors containing WT MSCs (p = 0.0314) (Figure 3C), as 
we had already shown for the HCmel12 tumors (Figure  2A). 
Finally, we asked whether the DKK3 produced by WT MSCs is 
responsible for the observed effect. Therefore, the RMA-mOVA 
tumor cells, which do not express DKK3, were injected into 
DKK3-deficient mice. Again, only the RMA-mOVA tumors 
injected together with WT MSCs could grow, while the tumors 
without MSC or with DKK3−/− MSCs were rejected (Figure 3D). 
This indicated that the DKK3 produced by MSCs, but neither 
by the tumor cells nor by the environment, might be capable 
of down-modulating the immune response against this trans-
planted tumor.
DiscUssiOn
Here, we demonstrate that DKK3 is an additional important 
soluble factor for MSCs to regulate immune responses in 
the tumor microenvironment. Loss of DKK3 impaired the 
immune-suppressive capacity of MSCs resulting in rejection 
of transplanted tumors, which were accepted in the presence 
of DKK3-sufficient MSCs. Increased CD8+ T cell and reduced 
M2-type macrophages infiltration were observed in tumors 
containing DKK3−/− MSCs.
Many studies have demonstrated that MSCs can promote 
tumor growth and formation of metastasis, whereas other 
studies reported that MSCs suppress tumor progression (28). 
Presently, there is no simple explanation for these conflicting 
findings. Further investigations are needed for a better under-
standing of the interactions between MSCs and cells present 
in a tumor, especially because of the therapeutic potential of 
MSCs. Therefore, we have chosen two models of tumor trans-
plants whose progression is supported by MSCs to investigate 
the role of DKK3. Although DKK3−/− MSCs were normally 
persistent within the tumor transplants, they did not accelerate 
tumor growth in C57BL/6 mice as WT MSCs did. We observed 
an increase in CD105+ cells among the DKK3−/− MSCs. It was 
recently reported that CD105− MSCs represent an independ-
ent subpopulation (29). The CD105+ and CD105− mMSC 
subpopulations had similar growth potential, but varied in 
their immunoregulatory properties. Interestingly, CD105− 
mMSCs suppressed the proliferation of CD4+ T cells more 
efficiently in comparison with CD105+ mMSCs. Therefore, it 
is possible that losing DKK3 promotes the differentiation and/
or the survival of the CD105+ MSC subpopulation and leads 
to a reduction in the suppressive capacity of DKK3−/− MSCs. 
It had been reported that DKK3 produced by human MSCs 
could decrease cell cycle progression of tumor cells in  vitro 
(19). Presently, we cannot judge whether or not DKK3 can 
directly modulate the growth of the used tumor transplants 
in  vivo. However, we would like to conclude that DKK3 is 
contributing to the immune-suppressive capacity of MSCs 
because DKK3 could reduce tumor infiltration by CD8+ T 
cells, which had been shown to contribute to the rejection of 
RMA-mOVA tumors (28). This is in concordance with our 
recent reports in which DKK3 could limit CD8+ and CD4+ T 
cell-mediated responses (20–22).
Molecular mechanisms of DKK3 functions are still unknown. 
So far, no surface receptor for DKK3 has been identified in mice 
or humans. It has been reported that recombinant human DKK3 
could be internalized by induced pluripotent stem cell-derived 
embryoid bodies via endocytosis (30). Such an internalization 
process may explain how DKK3 could interact with the cyto-
plasmic protein b-TrCP, thereby acting as a negative regulator 
of Wnt signaling (31). Therefore, it is possible that the immune-
modulatory function of DKK3 may be based at least in part on 
its modulation of the Wnt pathway, especially as Wnt signaling 
is known to influence T-cell effector function (32) and linage 
commitment (33). However, the distinct cellular and molecular 
mechanisms through which DKK3 mediates its function warrant 
further investigation.
Dickkopf-3 is also known as “REIC” (Reduced Expression 
in Immortalized Cells), as it was discovered in transcriptome 
screening of primary tumors (34). Since then numerous reports 
proposed that DKK3 can act as a tumor suppressor. DKK3 has 
been claimed to be downregulated in a broad range of cancers, 
such as non-small cell lung cancer (35), breast cancer (36, 37), 
gastric cancer (38), and melanoma (39), and this reduced expres-
sion was correlated with lower survival rates of patients from 
the respective cancer types. In contrast, deletion at the DKK3 
locus was related with lower lymph node metastasis and better 
prognosis in head and neck squamous cell carcinomas (40), 
indicating that DKK3 in this type of cancer is apparently not 
acting as a tumor suppressor but may more likely function as 
an immune modulator, as we have shown here and in previous 
studies (20–22). Thus the exact role and possible application of 
DKK3 may be dependent on the type of tumor and the cellular 
context.
Overall, our studies provide evidences that DKK3 is contribut-
ing to the immune-suppressive function of MSCs and may explain 
FigUre 3 | DKK3 expression exclusively by Mscs is sufficient to limit T cell responses against the strongly antigenic rMa-mOVa tumor. When 
inoculating 4 × 105 RMA-mOVA tumor cells, which did not express autologous DKK3 (a), along with equal cell number of MSCs, (B) tumors with wild-type 
DKK3-competent MSCs (⚪, n = 6) kept significant growth without rejection in comparison with tumors containing DKK3-deficient MSCs (▪, n = 6) or without any 
MSC (⚫, n = 6) (p < 0.0001 or p < 0.0001). No difference in tumor growth could be distinguished between tumors with DKK3−/− MSCs and tumors without any 
MSC (p = 0.8516). (c) By inoculating RMA-mOVA cells with either wild-type (⚬, n = 17) or DKK3−/− MSCs (⚫, n = 14) or without any MSC (▪, n = 7) into EGFP+ B6 
mice, tumor-infiltrating immune cells in the isolated tumor nodules were identified as EGFP+ cells after 14 days. Tumor-infiltrating CD8+ T cells were significantly 
increased in DKK3−/− MSC-inoculated tumors in comparison with tumors with wild-type MSCs (p = 0.0314). No difference was observed between tumors only and 
tumors containing either WT or DKK3−/− MSCs (p = 0.1190 or p = 0.8186). Two independent experiments were performed. (D) In DKK3−/− mice, growth of 
RMA-mOVA tumors was only observed when tumor cells were co-injected with DKK3-competent MSCs (⚬, n = 6), which was in contrast to tumors inoculated with 
DKK3-deficient MSCs (▪, n = 6) or without any MSC (⚫, n = 6) (p < 0.0001 or p < 0.0001). No difference in tumor growth was observed between tumors harboring 
DKK3−/− MSCs and tumors without any MSC (p = 0.4166). ANOVA followed by the Holm-Šídák approach to multiple comparisons was applied.
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the underlying mechanism in those cancer types that show better 
prognosis associated with impaired DKK3 expression. In addi-
tion, our findings strongly suggest careful considerations whether 
or not DKK3 may be used as a therapeutic “agent” or “target” in 
the treatment of cancers (41).
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